Zhejiang Cancer Hospital

Fapon Biopharma Enrolls First Patient in Phase I Trial of FP008, Novel Anti-PD-1 Fusion Protein for Solid Tumors

- Fapon Biopharma has enrolled the first patient in China for its Phase I clinical trial of FP008, a first-in-class anti-PD-1 × IL-10M fusion protein immunotherapy for advanced solid tumors. - The novel therapy is designed to overcome limitations of current PD-1 inhibitors and offers potential treatment for patients who are refractory to or relapsed from anti-PD-1/PD-L1 therapies. - Preclinical studies demonstrated FP008 significantly reduces CD8⁺ T-cell exhaustion and exhibits potent anti-tumor efficacy with enhanced T-cell infiltration into tumors. - The first patient has completed the Dose Limiting Toxicity observation period with a favorable safety profile, and FP008 has received IND approval from both FDA and China's NMPA.